Related Experiment Video
Updated: Oct 17, 2025
10:25
Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection
Published on: June 5, 2021
4.9K
Broadly-Neutralizing Antibodies Against Emerging SARS-CoV-2 Variants
Lok Bahadur Shrestha1,2, Nicodemus Tedla1, Rowena A Bull1,2
1School of Medical Sciences, Faculty of Medicine, Sydney, NSW, Australia.
Frontiers in Immunology
|October 14, 2021
Summary
New therapeutic monoclonal antibodies (mAbs) are crucial for combating SARS-CoV-2 variants. This review highlights promising broadly neutralizing antibodies effective against current and emerging viral strains.
Area of Science:
- Virology
- Immunology
- Drug Discovery
Background:
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants like Alpha, Beta, Gamma, and Delta exhibit reduced sensitivity to existing antibody therapies.
- This reduced sensitivity poses a significant challenge to controlling the ongoing pandemic and necessitates the development of new therapeutic strategies.
Purpose of the Study:
- To review promising broadly neutralizing monoclonal antibodies (mAbs) derived from early SARS-CoV-2 convalescent plasma.
- To assess the potential efficacy of these mAbs against emerging SARS-CoV-2 variants and other Sarbecoviruses.
Main Methods:
- Literature review of studies identifying and characterizing broadly neutralizing antibodies against SARS-CoV-2.
- Analysis of antibody cross-neutralization data against various SARS-CoV-2 variants and related sarbecoviruses.
Main Results:
- Several broadly neutralizing mAbs have been identified that demonstrate cross-neutralization capabilities against SARS-CoV-2 variants and escape mutants.
- These antibodies show potential for broad efficacy, offering a promising avenue for therapeutic intervention.
Conclusions:
- Understanding the mechanisms behind broad and cross-neutralization is key for developing next-generation therapeutic antibodies.
- This knowledge can also guide the design of improved vaccines to provide broader protection against evolving coronaviruses.
